Geographic Atrophy

Healio spoke with Nathan M. Radcliffe, MD, about the best practices for monitoring glaucoma progression.

Healio spoke with Nathan M. Radcliffe, MD, about the evolution of glaucoma care.

Healio spoke with Nathan M. Radcliffe, MD, about exciting new advancements in the treatment of glaucoma.

Healio spoke with Nathan M. Radcliffe, MD, about discussing treatment options for glaucoma with patients.

CHICAGO — In this Healio Video Perspective from Eyecelerator@AAO, Sharon Bakalash, MD, PhD, CBA, of Astellas Ophthalmics, discusses the company’s pipeline for geographic atrophy as well as AI’s growing role in treating the condition.

The data and safety monitoring board for a phase 1/2 study clinical trial of a geographic atrophy gene therapy approved continuation of the second phase of the study due to positive safety results, according to a press release from Ocugen.

In 2024, Healio covered several stories about trials investigating geographic atrophy biomarkers and treatment options.

CHICAGO — In this Healio Video Perspective from the AAO meeting, Rahul N. Khurana, MD, of Northern California Retina Vitreous Associates discusses phase 2 results for ANX007 for the treatment of geographic atrophy.

BARCELONA, Spain — In the phase 2 ARCHER trial, ANX007, a novel C1q inhibitor with neuroprotective properties, showed consistent protection against loss of visual acuity in eyes with geographic atrophy.